2Callis L, Vila A, Carrera M, et al. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int, 1999,55 (3) : 1051 - 1056.
3Wei G, Zhihong L, Huiping C, et al. Spectrum of clinical features and type IV collagen alpha-chain distribution in Chinese patients with Alport syndrome. Nephrol Dial Transplant, 2006, 21 ( 11 ) : 3146 -3154.
4Chen D, Jefferson B, Harvey SJ, et al. Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis) :results from a canine model. J Am Soc Nephrol,2003,14 ( 3 ) :690 - 698.
5Sigmundsson TS, Palsson R, Hardarson S, et al. Resolution of proteinuria in a patient with X-linked Alport syndrome treated with cyelosporine. Scand J Urol Nephrol, 2006,40 ( 6 ) :522 - 525.
6Li JG, Ding J, Wang F, et al. Drugs controlling proteinuria of patients with Alport syndrome. World J Pediatr,2009,5 (4) : 308 - 311.
7Massella L, Muda AO, Legato A, et al. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol,2010,25 (7) : 1269 - 1275.
8Kuypers DR, Naesens M, de Jonge H, et al. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit ,2010,32 (4) : 394 - 404.
9Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol,2010,25 (7) : 1197 - 1199.
10Chen ZH, Qin WS, Zeng CH, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9- induced podocyte injury in vitro. Kidney Int ,2010,77( 11 ) :974 -988.
